Machine learning-guided rational engineering of ACE2-derived peptides for broad-spectrum neutralization of SARS-CoV-2 variants
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The dynamic mutational landscape of SARS-CoV-2, especially within the spike glycoprotein's RBD, continues to undermine the effectiveness of available therapeutics. Although ACE2-derived peptides have previously been explored as spike inhibitors, their rational optimization has largely lacked systematic, data-driven selection strategies. This article describes an integrative computer-aided approach involving molecular dynamics (MD) simulations and machine learning-assisted peptide engineering to engineer potent peptide-based inhibitors targeting the RBD–ACE2 interface. Molecular dynamics simulations of wild-type and variant RBD–ACE2 complexes were first employed to identify energetically unfavorable interfacial residues, enabling the rational extraction and refinement of a 19-residue ACE2-derived peptide. A supervised regression model of the type XGBoost, trained using experimentally obtained peptide-protein affinity matrices (R2 = 0.6958), estimated binding potentials for 54 synthetically designed peptide variants. The best lead, M1 (HAHTFLETFNYEAQTLSYE), exhibited improved docking energies (–257.35 kcal/mol for Omicron and –234.24 kcal/mol for wild-type) and improved free-binding energies (–35.67 kcal/mol and –21.63 kcal/mol, respectively), relative to the native peptide, with binding energies comparable to or exceeding reported RBD–hACE2 interaction benchmarks (− 13 to − 18 kcal/mol). Molecular dynamics analyses further confirmed enhanced conformational stability, sustained hydrogen bonding, and favourable energetic landscapes for the M1–RBD complexes. Collectively, this study demonstrates that integrating energetic decomposition with ML-driven peptide optimization provides a scalable and mechanistically informed strategy for developing peptide-based inhibitors against rapidly evolving viral pathogens.
Fields of Study & Subjects
SARS-CoV-2 and COVID-19 Research
vaccines and immunoinformatics approaches
Computational Drug Discovery Methods
Publication details
- Journal / source
- Saudi Pharmaceutical Journal
- Volume
- 34
- Issue
- 2
- Pages
- 17
- Publication date
- 31 March 2026
- Language
- EN